Latest market price
20.13
-0.73-3.50%
OverviewShort InterestFilings
ASMBQT24Assembly Biosciences, Inc.·NASDAQ
20.13-3.50%
News
Down 3.5% — Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta Virus (globenewswire.com).
Medium confidence
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
TRAX-0.33%$45.08NVAX-3.72%$10.08NUVB-0.21%$4.76KLRA-4.10%$12.86REPL+1.27%$17.61STOK-0.23%$26.29QURE-1.86%$24.83NTLA-5.74%$12.47
Snapshot
Index—P/E36.60EPS (ttm)0.55Insider Own—Shs Outstand20.36MPerf Week1.46%
Market Cap409.86MForward P/E—EPS next Y-3.05Insider Trans-0.00%Shs Float12.80MPerf Month-12.40%
Enterprise Value91.86MPEG—EPS next Q-0.65Short Float22.76%Perf Quarter-20.62%
Income0.00P/S5.54EPS this Y—Short Ratio10.25Perf Half Y-26.45%
Sales74.00MP/B1.34EPS next Y—ROA-0.01%Short Interest2.91MPerf YTD-40.81%
Book/sh15.03P/C1.28EPS next 5Y—ROE-0.02%52W High39.71 -49.31%Perf Year-35.04%
Cash/sh15.72P/FCF—EPS past 3/5Y—ROIC-2.86%52W Low19.30 4.30%Perf 3Y102.11%
Dividend Est.—EV/EBITDA—Sales past 3/5Y— -1.84%Gross Margin77.73%Volatility4.02% 4.88%Perf 5Y-46.41%
Dividend TTM—EV/Sales1.24EPS Y/Y TTM—Oper. Margin-11.76%ATR (14)1.08Perf 10Y-87.40%
Dividend Ex-Date—Quick Ratio13.99Sales Y/Y TTM124.24%Profit Margin-0.06%RSI (14)35.86Recom2.45
Dividend Gr. 3/5Y—Current Ratio13.99EPS Q/Q84.96%SMA20-4.59%Beta1.24Target Price51.67
Payout0.00%Debt/Eq0.01Sales Q/Q30.00%SMA50-23.00%Rel Volume0.47Prev Close20.86
Employees73LT Debt/Eq0.01EarningsNov 09SMA200-25.99%Avg Volume294.16KPrice20.13
IPO DateDec 17, 2010Option/ShortYes / YesEPS/Sales Surpr.72.38% 55.53%Net Debt/EBITDA—Volume136,867Change-3.50%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-01-26ReiteratedUBS$52
Sep-01-26ReiteratedMizuhoOutperform$45 → $53
Aug-18-26ReiteratedHC Wainwright & Co.Buy$50
Jun-15-26ReiteratedMizuhoOutperform$40 → $45
Nov-20-25ReiteratedMizuhoOutperform$36 → $40
Sep-24-25InitiatedCitizens JMPOutperform$38
Sep-24-24ReiteratedMizuho SecuritiesBuy$36
Sep-20-24ReiteratedJefferiesHold$35
Oct-23-22DowngradeTruist SecuritiesBuy → Hold
Sep-01-21DowngradeWilliam BlairOutperform → Market Perform
Latest News· Times ET
Oct-29-26
Oct-29-2604:00PM
Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta Virusglobenewswire.com
Oct-06-26
Oct-06-2606:15AM
Analyzing RYTHM (NASDAQ:RYM) and Assembly Biosciences (NASDAQ:ASMB)defenseworld.net
Oct-05-26
Oct-05-2610:00AM
Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026globenewswire.com
Sep-17-26
Sep-17-2611:00AM
Best Momentum Stocks to Buy for September 17thzacks.com
08:51AM
New Strong Buy Stocks for September 17thzacks.com
Sep-10-26
Sep-10-2604:15PM
Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conferenceglobenewswire.com
Sep-09-26
Sep-09-2609:46AM
Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive Pickszacks.com
Sep-08-26
Sep-08-2604:00PM
Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Programglobenewswire.com
Sep-07-26
Sep-07-2610:55AM
Wall Street Analysts See a 35.71% Upside in Assembly Biosciences (ASMB): Can the Stock Really Move This High?zacks.com
Sep-04-26
Sep-04-2611:15AM
Should You Buy Assembly Biosciences (ASMB) After Golden Cross?zacks.com
10:01AM
5 Stocks With Recent Price Strength Buoyed by a Strong Augustzacks.com
Sep-03-26
Sep-03-2609:56AM
Here's Why Momentum in Assembly Biosciences (ASMB) Should Keep goingzacks.com
Sep-01-26
Sep-01-2606:49AM
Mizuho Maintains Outperform on Assembly Biosciences, Lowers Price Target to $45Benzinga
Aug-25-26
Aug-25-2611:01AM
Best Momentum Stocks to Buy for August 25thzacks.com
08:05AM
New Strong Buy Stocks for August 25thzacks.com
Company

Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue7472297—————
Cost of Goods Sold Incl. D&A1705649—————
Gross Profit5772-27-42—————
Selling, General and Administrative Excl. Other20201823—————
Research and Development64655649—————
Other Operating Expense-16-1-56-49—————
Operating Income-8-12-45-65—————
Interest Expense
0000—————
Unusual Expense
—————————
Non-Operating Income (Expense)8663—————
Net Income Before Taxes0-6-40-61—————
Income Taxes
0000—————
Consolidated Net Income0-6-40-61—————
Net Income From Continuing Operations0-6-40-61—————
Net Income0-6-40-61—————
EPS (Recurring)0.55-0.55-6.69-13.38—————
EPS (Basic, Before Extraordinaries)0.55-0.55-6.69-13.38—————
EPS (Diluted)0.55-0.55-6.69-13.38—————
EBITDA0-6-40-61—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
36.60————————
Price To Sales Ratio5.175.203.267.03—————
Gross Margin77.03100.00-93.10-600.00—————
Operating Margin-10.81-16.67-155.17-928.57—————
Net Margin0.00-8.33-137.93-871.43—————
Shares Outstanding191165—————
Market Capitalization3823749549—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$41.32$35.20$29.09$22.97$16.85● Close Price0.00K3.50K7.01K10.51K14.01KUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Bjorkquist Jeanette MPFO and PAOJun 17 '26Sale23.252967414,560Jun 18
White Nicole SChief Manufacturing OfficerMar 30 '26Sale26.691975,25737,477Mar 31
Bjorkquist Jeanette MPFO and PAOMar 30 '26Sale26.693288,75511,089Mar 31
GILEAD SCIENCES, INC.10% OwnerAug 08 '25Buy10.804,591,84049,594,1684,505,391Oct 03
McHutchison John GDirectorMar 31 '25Sale9.857577,45518,347Apr 15
Okazaki Jason ACEO and PresidentMar 31 '25Sale9.853553,49614,757Apr 01
Bjorkquist Jeanette MPrincipal Accounting OfficerMar 31 '25Sale9.851801,7734,617Apr 01
White Nicole SChief Manufacturing OfficerMar 31 '25Sale9.851971,94011,674Apr 01
Houghton MichaelDirectorDec 30 '24Buy15.613,20249,9983,202Dec 31
GILEAD SCIENCES, INC.10% OwnerDec 19 '24Buy21.37940,49920,098,4642,209,471Dec 23
Schornstein Alexander10% OwnerNov 25 '24Buy14.917,976118,890728,113Nov 26
Schornstein Alexander10% OwnerNov 22 '24Buy14.8717,024253,104720,137Nov 26
White Nicole SChief Manufacturing OfficerNov 18 '24Sale16.294065211,871Nov 19
Schornstein Alexander10% OwnerOct 08 '24Buy14.5810,000145,800703,113Oct 09
Okazaki Jason ACEO and PresidentOct 03 '24Sale14.811972,91814,904Oct 04
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.